
@cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update. To read the press release cellectis.com/en/press/celle…

Cellectis is a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment.

@cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update. To read the press release cellectis.com/en/press/celle…

Cellectis to Report Third Quarter Financial Results on November 12, 2026. To read the announcement: cellectis.com/en/press/celle…

Today at the European Society of Gene and Cell Therapy, we are presenting preclinical data on .HEAL-101, our in vivo base editing product candidate targeting APOC3 for severe hypertriglyceridemia. To read the full press release: shorturl.at/ZXMo6 #ESGCT2026

Et si une seule administration permettait de traiter à la source certaines maladies cardiométaboliques sévères ? André Choulika était l'invité de @bfmbusiness pour échanger sur les nouvelles perspectives ouvertes par l'édition du génome: tinyurl.com/m8fwzhcm

Pourquoi arrêter un programme clinique qui venait d’obtenir le statut RMAT de la FDA ? André Choulika répond dans Le Journal des Biotechs de @Boursorama. Il y explique la transformation de Cellectis en société d’édition du génome in vivo >> shorturl.at/cbu8n

Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company. To read the press release: cellectis.com/en/press/celle…

Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update. To read the press release: cellectis.com/en/press/celle…

@cellectis announces participation in upcoming investor conferences. To read the press release: shorturl.at/lXN44

Cellectis Reports Financial Results for the Second Quarter 2026. To read the press release: cellectis.com/en/press/celle…

#Cellectis to Report Second Quarter Financial Results on August 6, 2026. Full press release here: cellectis.com/en/press/celle…

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026. Read the full press release here: cellectis.com/en/press/celle…

Today at #EHA2026, we shared final Ph1 results from BALLI-01, evaluating lasme-cel in patients with r/r B-ALL. *100% ORR in the target Ph2 population (n=7) *All responding patients proceeded to transplant *Manageable safety profile Full press release: cellectis.com/en/press/celle…

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL. To read the press release: cellectis.com/en/press/celle…

#Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026. Full press release here : cellectis.com/en/press/celle…

Cellectis announced two presentations at the @EHA_Hematology >> Lasme-cel - Oral presentation | June 13 >> Eti-cel - Poster presentation | June 13 To read the press release: cellectis.com/en/press/celle…

Cellectis Reports Financial Results for the First Quarter 2026. To read the press release: cellectis.com/en/press/celle…